Boothbay Fund Management LLC Purchases Shares of 352,206 Tenax Therapeutics, Inc. $TENX

Boothbay Fund Management LLC acquired a new position in shares of Tenax Therapeutics, Inc. (NASDAQ:TENX) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 352,206 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,680,000. Boothbay Fund Management LLC owned approximately 7.72% of Tenax Therapeutics at the end of the most recent reporting period.

Separately, Virtu Financial LLC purchased a new stake in Tenax Therapeutics in the 3rd quarter valued at approximately $92,000. Hedge funds and other institutional investors own 1.67% of the company’s stock.

Tenax Therapeutics Price Performance

Shares of TENX stock opened at $13.98 on Tuesday. The firm’s 50-day simple moving average is $13.38 and its 200-day simple moving average is $10.07. Tenax Therapeutics, Inc. has a 1-year low of $4.63 and a 1-year high of $18.38. The firm has a market cap of $87.29 million, a P/E ratio of -10.51 and a beta of 1.41.

Tenax Therapeutics (NASDAQ:TENX) last released its earnings results on Tuesday, March 10th. The specialty pharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.26) by $0.88. Analysts expect that Tenax Therapeutics, Inc. will post -0.88 earnings per share for the current fiscal year.

Analyst Ratings Changes

TENX has been the topic of a number of analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tenax Therapeutics in a report on Monday, December 22nd. William Blair restated an “outperform” rating on shares of Tenax Therapeutics in a research report on Tuesday, March 10th. Lifesci Capital raised Tenax Therapeutics to a “strong-buy” rating in a research note on Thursday, March 12th. Finally, Guggenheim lifted their price objective on Tenax Therapeutics from $25.00 to $34.00 and gave the stock a “buy” rating in a research report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Tenax Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $27.00.

Tenax Therapeutics Profile

Tenax Therapeutics, Inc is a clinical-stage specialty pharmaceutical company developing drug delivery technologies designed to improve pain management in acute care settings. The company’s proprietary platform leverages biodegradable polymer matrices to create sustained-release formulations of local anesthetics, aiming to extend the duration of pain relief while reducing reliance on opioid medications.

Tenax’s lead development programs focus on injectable formulations intended for infiltration and peripheral nerve block applications, with the goal of providing longer-lasting analgesia following surgical and procedural interventions.